-
The adverse publicity following publications from the Women's Health Initiative was a multibillion dollar bonanza for compounding pharmacies providing postmenopausal hormones.
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
Inhaled salmeterol and fluticasone, singly or in combination, reduce the rate of decline of the FEV1 in patients with moderate-to-severe COPD.
-
CT colonographic screening of asymptomatic adults identified 90% of polyps or cancers measuring 10 mm or more.
-
Homocysteine (HCYS) has all the trappings of a first-rate cardiovascular risk factor: as strong an association with CVD endpoints as cholesterol, ease of identification, and simplicity of modulation. Trouble is, trials to date have been unable to show that reductions of homocysteine provide meaningful benefits to patients.
-
Intensive hemoglobin A1c lowering does not reduce the rate of cardiovascular death, and results in an increase in hypoglycemic events.
-
When it comes to oral contraceptives (OCs), what is your current practice when it comes to prescribing pills in extended- or continuous- regimens? More providers are prescribing pills in this manner, say respondents to the 2008 Contraceptive Technology Update Contraception Survey. About 62% say they increased use of such pill regimens in the last year.
-
Use of intrauterine contraception is slowly gaining ground among U.S. women. About 45% of respondents to the 2008 Contraceptive Technology Update Contraception Survey say they inserted six or more devices in the last year, compared to 2007's 40% figure. About 40% reported no insertions in 2008, similar to 2007's statistic.
-
To prevent pregnancy and disease in adolescents, health professionals seek to help teens delay sexual activity and increase condom and contraception use among those who are sexually active. Throughout the 1990s, those efforts appeared successful.
